MP-1 detects early retinal sensitivity loss in diabetics

Article

The microperimeter (MP-1) is ideal for detecting early retinal sensitivity loss in diabetic patients.

The microperimeter (MP-1) is ideal for detecting early retinal sensitivity loss in diabetic patients, claims a recent investigation in Retina.

Dr M.G. Nittala et al., Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralaya, Chennai, Tamil Nadu, India, completed several ophthalmic examinations on 210 eyes of 160 patients. This included best-corrected visual acuity, slit-lamp examination, indirect ophthalmoscopy and microperimetry. Subjects included healthy participants, diabetics with no retinopathy and patients suffering from different stages of diabetic retinopathy (DR).

Retinal sensitivity significantly decreased in correlation to DR severity. Mean foveal sensitivity was 16.68 ± 2.13 dB in healthy participants, 14.73 ± 3.64 dB in diabetics but no DR and 11.60 ± 5.76 dB in DR patients.

Diabetic patients with no DR experienced a significant loss of retinal sensitivity, compared to healthy subjects. Severe non-proliferative DR presented with a more significant loss of retinal sensitivity in he central 20, compared to those with other stages of DR.

The MP-1 is able to detect retinal sensitivity loss at an earlier stage in diabetic patients without DR. It is also a useful tool for measuring retinal sensitivity in DR patients. The MP-1 features scotomoa mapping, enabling the detection of functional vision in DR patients.

The abstract can be seen here.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.